Tokyo Pharma Licenses Rosetta's Biomarker Software | GenomeWeb
NEW YORK (GenomeWeb News) - Japanese pharmaceutical company Eisai has licensed Rosetta Biosoftware's Elucidator protein expression and biomarker discovery system, Rosetta said yesterday.
 
Seattle-based Rosetta said Eisai plans to use the Elucidator system to support LC/MS methods for biomarker research in neurology at the Laboratory of Seeds Finding Technology
 
Elucidator enables data management and analysis workflow for comparative proteomics, Rosetta said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.